Melasma: Treatment strategy

References

• McDonald RR, Georgouras KE. Skin Disorders in Indo-Chinese immigrants. Med J Aust. 1992;156:847–853.
   PubMedGoogle Scholar
• Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593–596.
   PubMed Web of Science ®Google Scholar
• Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men: a clinical, aetiological and histological study. J Eur Acad Dermatol Venereol. 2010;24:768–772.
   PubMedGoogle Scholar
• Sanchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sanchez JL, . Melasma: A clinical light microscopic, ultrastructural, and immunofluorescence study. J Am Acad Dermatol. 1981;4:698–710.
   PubMed Web of Science ®Google Scholar
• Moin A, Jabery Z, Fallah A. Prevalence and awareness of melasma during pregnancy. Int J Dermatol. 2006;45: 285–288.
   PubMedGoogle Scholar
• Goh CL, Dlova CN. A retrospective study on the clinical presentation and treatment outcome of melasma in a tertiary dermatological referral centre in Singapore. Singapore Med J. 1999;40:455–488.
   PubMedGoogle Scholar
• Abaraca J. Melasma in pregnancy. Med Cutan Iberolat Am. 1987;15:199–203.
   PubMedGoogle Scholar
• Adalatkhah H, Sedeghi-bazargani H, Amini-sani N, Zeynizadeh S. Melasma and its association with different types of nevi in women: A case control study. BMC Dermaotol. 2008;8:3.
   PubMedGoogle Scholar
• Muzaffar F, Hussain I, Haroon TS. Physiologic skin changes during pregnancy: A study of 140 cases. Int J Dermatol. 1998;37:429–431.
   PubMedGoogle Scholar
• Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, . A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol. 2009;23:1254–1262.
   PubMed Web of Science ®Google Scholar
• Halaban R, Hebert DN, Fisher DE. Biology of melanocytes. In: Freedberg IM, Eisen AZ, Wolff K, Austen FK, Goldsmith LA, Katz SI, editors. Dermatology In General Medicine. 6th ed. New York, NY: McGraw Hill Medical Publishing; 2003. pp. 127–148.
   Google Scholar
• Ortonne JP, Bahadoran P, Fitzpatrick TB, . Hypomelanosis and hypermelanosis. In: Freedman IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick’s Dermatology in General Medicine. McGraw Hill: New York; 2003. pp. 836–881.
   Google Scholar
• Ando H, Ryu A, Hashimoto A, Oka M, Ichihashi M. Linoleic acid and alpha-linolenic acid lightens ultraviolet-induced hyperpigmentation of the skin. Arch Dermatol Res. 1998;290:375–381.
   PubMed Web of Science ®Google Scholar
• Ando H, Watabe H, Valencia JC, Yasumoto K, Furumura M, . Fatty acids regulate pigmentation via proteasomal degradation of tyrosinase: A new aspect of ubiquitin-proteasome function. J Biol Chem. 2004;279:15427–15433.
   PubMed Web of Science ®Google Scholar
• The chemistry of melanin: III. Mechanism of the oxidation of dihydroxyphenylalanine by tyrosinase. Howard S Mason J Biol Chem. 1948;172:83–99.
   PubMedGoogle Scholar
• Raper HS. The Aerobic Oxidases. Physiol Rev. 1928;8: 245–258.
   Google Scholar
• Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol. 1986;15:894–899.
   PubMed Web of Science ®Google Scholar
• Im S, Lee ES, Kim W, On W, Kim J, . Donor specific response of estrogen and progesterone on cultured human melanocytes. J Korean Med Sci. 2002;17:58–64.
   PubMed Web of Science ®Google Scholar
• Kim NH, Lee CH, Lee AY. H19 RNA downregulation stimulated melanogenesis in melasma. Pigment Cell Melanoma Res. 2010;23:84–92
   PubMed Web of Science ®Google Scholar
• Hernández-Barrera R, Torres-Alvarez B, Castanedo-Cazares JP, Oros-Ovalle C, Moncada B. Solar elastosis and presence of mast cells as key features in the pathogenesis of melasma. Clin Exp Dermatol. 2008;33:305–308.
   PubMedGoogle Scholar
• Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2001;18:91–98.
   Google Scholar
• Cunningham FG, MacDonald PC, Leveno KJ, . Maternal adaptations to pregnancy. In: Williams J, ed. Williams Obstrectis. 19th ed. Prentice-Hall, USA; 1993. p. 215.
   Google Scholar
• Bolanca I, Bolanca Z, Kuna K, Vuković A, Tuckar N, . Chloasma—the mask of pregnancy. Coll Antropol. 2008;2:139–141.
   Google Scholar
• Resnik S. Melasma induced by oral contraceptive drugs. J Am Med Assoc. 1967;199:601–605.
   PubMed Web of Science ®Google Scholar
• Parker F. Skin and hormones. In: Williams RH, ed. Textbook of Endocrinology. 6th ed. Philadelphia: WB Saunders Co; 1981. pp. 1088–1091.
   Google Scholar
• Johnston GA, Sviland L, McLelland J. Melasma of the arm associated with hormone replacement therapy. Br J Dermatol. 1998;139:932.
   PubMed Web of Science ®Google Scholar
• Esoda E. Chloasma from progestational and contraceptives. Arch Dermatol. 1963;87:486.
   Google Scholar
• Perez M, Sanchez JL, Aquilo F. Endocrinologic profile of patients with idiopathic melasma. J Invest Dermatol. 1983;81:543–545.
   PubMed Web of Science ®Google Scholar
• Jang YH, Lee JY, Kang HY, Lee ES, Kim YC. Oestrogen and progesterone receptor expression in melasma: An immunohistochemical analysis. J Eur Acad Dermatol Venereol. 2010;23: [Epub ahead of print].
   Google Scholar
• Lieberman R, Moy L. Estrogen receptor expression in melasma: Results from facial skin of affected patients. J Drugs Dermatol. 2008;7:463–465.
   PubMed Web of Science ®Google Scholar
• Lutfi RJ, Fridmanis M, Misiunas AL, Pafume O, Gonzalez EA, . Association of melasma with thyroid autoimmunity and other thyroid abnormalities and their relationship to the origin of melasma. J Clin Endocrinol Metab. 1985;61:28–31.
   PubMedGoogle Scholar
• Niepomniszcze H. Amad RH. Skin disorders and thyroid diseases. J Endocrinol Invest. 2001:24:628–638.
   PubMed Web of Science ®Google Scholar
• Sarkany I, Graham-Brown RAC. The hepatobiliary system and the skin. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, editors. Fitzpatrick's Dermatology in General Medicine. 4th ed. McGraw Hill; 1999. pp.1972.
   Google Scholar
• Bedi TR, Bhutani LK. Aetiological factors in chloasma. Br J Clin Pract. 1975;29:107–108.
   PubMedGoogle Scholar
• Kimbrough-Green CK, Griffiths CEM, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, . Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol. 1994;130:727–733.
   PubMed Web of Science ®Google Scholar
• Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am. J Dermatopathol. 2005;27:96–101.
   PubMedGoogle Scholar
• Hassan I, Kaur I, Sialy R, Dash RJ. Hormonal milieu in the maintenance of melasma in fertile women. J Dermatol. 1998;25:510–512.
   PubMedGoogle Scholar
• Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, . Melasma: histopathological characteristics in 56 Korean patients. Br J Dermatol. 2002;146:228–237.
   PubMed Web of Science ®Google Scholar
• Kang HY, Hwang JS, Lee JY, Ahn JH, Kim JY, . The dermal stem cell factor and c-kit are overexpressed in melasma. Br J Dermatol. 2006;154:1094–1099.
   PubMed Web of Science ®Google Scholar
• Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. Dermatol Sci. 2007;46:111–116.
   PubMed Web of Science ®Google Scholar
• Sarvjot V, Sharma S, Mishra S, Singh A. Melasma: A clinicopathological study of 43 cases. Indian J Pathol Microbiol. 2009;52:357–359.
   PubMedGoogle Scholar
• Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alterations in patients with melasma. Am J Dermatopathol. 2005;27:96–101.
   PubMedGoogle Scholar
• Aloi F, Solaroli C, Giovannini E. Actinic lichen planus simulating melasma. Dermatology. 1997:195:69–70.
   PubMedGoogle Scholar
• Pandya AG, Guevara IL. Disorders of hyperpigmentation. Dermatol Clin. 2000;18:91–98.
   PubMed Web of Science ®Google Scholar
• Piamphongsant T. Treatment of melasma: A review with personal experience. Int J Dermatol. 1998;37:897–903.
   PubMed Web of Science ®Google Scholar
• Serrano G, Pujol C, Cuadra J, Gallo S, Aliaga A. Riehl’s melanosis: pigmented contact dermatitis caused by fragrances. J Am Acad Dermatol. 1989;21:1057–1060.
   PubMed Web of Science ®Google Scholar
• Sun CC, Lü YC, Lee EF, Nakagawa H. Naevus fusco-caeruleus zygomaticus. Br J Dermatol. 1987;117:545–553.
   PubMed Web of Science ®Google Scholar
• Sarkar R, Sehgal VN. Skin peel. In: Sehgal VN, ed. Dermatologic surgery made easy. Ist ed. New Delhi: Jaypee; 2006. pp. 17–34.
   Google Scholar
• Pathak MA, Fitzpatrick TB, Nighiem P, . Sun protective agents: Formulations, effects and side effects. In: Freedberg IM, Eisen AZ, Fitzpatrick TB, editors. Dermatology in General Medicine. 5th ed. New York: McGraw Hill Inc; 1999. pp. 2742–2763.
   Google Scholar
• Diffey BL. When should sunscreen be reapplied. J Am Acad Dermatol. 2001;45:882–885.
   PubMed Web of Science ®Google Scholar
• Rhodes LE. Topical and systemic approaches for protection against solar radiation induced skin damage. Clin Dermatol. 1998;16:75–82.
   PubMedGoogle Scholar
• Rendon M, Berneburg M, Arellano I, . Treatment of melasma. J Am Acad Dermatol. 2006;54:272–281.
   PubMed Web of Science ®Google Scholar
• Jimbow K, Obata, H, Pathak MA, Fitzpatrick TB. Mechanism of depigmentation by hydroquinone. J Invest Dermatol. 1974;62:436–439.
   PubMed Web of Science ®Google Scholar
• Sanchez JL, Vazquez M. A hydroquinone solution in the treatment of melasma. Int J Dermatol. 1982;21:55–58.
   PubMed Web of Science ®Google Scholar
• Vázquez M, Sánchez JL. The efficacy of a broad-spectrumsunscreen in the treatment of melasma. A randomized double blinded controlled trial. Cutis. 1983;32:92–96.
   PubMed Web of Science ®Google Scholar
• Arndt KA, Fitzpatrick TB. Topical use of hydroquinone as a depigmentating agent. JAMA. 1965;194:965–967.
   PubMedGoogle Scholar
• Grimes PE. Melasma: Etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453–1457.
   PubMed Web of Science ®Google Scholar
• Engasser PE, Maibach HI. Cosmetics and dermatology: Bleaching creams. J Am Acad Dermatol. 1981;5: 143–147.
   PubMed Web of Science ®Google Scholar
• Findley GH, Morrison JGL, Simon IW. Exogenous ochronosis and pigmented millium from hydroquinone bleaching creams. Br J Dermatol. 1975;93:613–622.
   PubMedGoogle Scholar
• Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40–48.
   PubMed Web of Science ®Google Scholar
• Gano SE, Garcia RL. Topical tretinoin, Topical tretinoin, hydroquinone and betamethasone valerate in the therapy of melasma. Cutis. 1979;23:239–241.
   PubMedGoogle Scholar
• Nazzaro-Porro M. Azealic acid. J Am Acad Dermatol. 1987;17:1033–1041.
   PubMed Web of Science ®Google Scholar
• Baliña LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893–895.
   PubMed Web of Science ®Google Scholar
• Sivayathorn A, Verallo-Rowell V, Graupe K. Eur J Dermatol. 1995;5:680–684.
   Google Scholar
• Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double blind comparison of azealic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl. 1989;143:58–61.
   PubMedGoogle Scholar
• Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker skinned patients: A clinical comparison with hydroquinone. Clin Ther. 1998;20:960–970.
   PubMed Web of Science ®Google Scholar
• Lerner AB, Fitzpatrick TB. Biochemistry of melanin formation. Physiol Rev. 1950;30:91–126.
   PubMed Web of Science ®Google Scholar
• Njoo MD, Menke HE, Pavel W, . N-Acetyl cysteine as a bleaching agent in treatment of melasma. J Eur Acad Derma Venereol. 1997;9:86–87.
   Google Scholar
• Orlow SJ, Chakraborty AK, Pawelek JM. Retinoic acid as a potent inhibitor of inducible pigmentation in murine and hamster melanomma cell lines. J Invest Dermatol. 1990;94:461–464.
   PubMed Web of Science ®Google Scholar
• Griffiths CEM, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, . Topical tretinoin (retinoic acid) improves melasma. A vehicle controlled clinical trial. Br J Dermatol. 1993;129: 415–421.
   PubMed Web of Science ®Google Scholar
• Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, . Topical retinoic acid (tretinoin) for melasma in black patients. Arch Dermatol. 1994;130:727–733.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, . Topical tretinoin (retinoic acid) improves melasma vehicle-controlled, clinical trial. Br J Dermatol. 1993;129: 415–421.
   PubMed Web of Science ®Google Scholar
• Ghersetich I, Troiano M, Brazzini B, Arunachalam M, Lotti T. Melasma:treatment with 10% tretinoin peeling mask. J Cosmet Dermatol. 2010;9:117–121.
   PubMedGoogle Scholar
• Gilchrist BA, Fitzpatrick TB, Anderson RR, Parrish JA. Localization of melanin pigmentation in the skin with the Wood's lamp. Br J Dermatol. 1977;96:245–248.
   PubMedGoogle Scholar
• Kang HY, Valerio L, Bahadoran P, Ortonne JP. The role of topical retinoids in the treatment of pigmentary disorders: An evidence-based review. Am J Clin Dermatol. 2009;10: 251–260.
   PubMed Web of Science ®Google Scholar
• Kanwar AJ, Dhar S, Kaur S. Treatment of melasma with potent topical corticosteroids. Dermatology. 1994;188:170.
   PubMed Web of Science ®Google Scholar
• Tirado-Sánchez A, Santamaría-Román A, Ponce-Olivera RM. Efficacy of dioic acid compared with hydroquinone in the treatment of melasma. Int J Dermatol. 2009;48:893–895.
   PubMed Web of Science ®Google Scholar
• Tadokoro T, Bonté F, Archambault JC, Cauchard JH, Neveu M, . Whitening efficacy of plant extracts including orchid extracts on Japanese female skin with melasma and lentigo senilis. J Dermatol. 2010;37:522–530.
   PubMedGoogle Scholar
• Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40–48.
   PubMed Web of Science ®Google Scholar
• Westerhof W, Njoo MD. Bleaching agents. In: Katsambas AD, Lotti TM, editors. European handbook of dermatological treatments. Berlin: Springer; 1999. pp. 766–77.
   Google Scholar
• Chan R, Park KC, Lee MH, Lee ES, Chang SE, . A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma. Br J Dermatol. 2008;159:697–703.
   PubMed Web of Science ®Google Scholar
• Grimes PE, Bhawan J, Guevara IL, Colón LE, Johnson LA, . Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. J Am Acad Dermatol. 2010;62:962–967.
   PubMed Web of Science ®Google Scholar
• Pathak MA, Fitzpatrick TB, Kraus EW. Usefulness of retinoic acid in the treatment of melasma. J Am Acad Dermatol. 1986;15:894–899.
   PubMed Web of Science ®Google Scholar
• Taylor SC, Torok H, Jones T, Lowe N, Rich P, . Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67–72.
   PubMed Web of Science ®Google Scholar
• Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22:443–447.
   PubMed Web of Science ®Google Scholar
• Kameyama K, Sakai C, Kondoh S. Inhibitory effects of magnesium-L-ascorbyl-2-phosphate (VC- PMG) on melanogenesis in- vitro and in-vivo. J Am Acad Dermatol. 1996;34:29–33.
   PubMed Web of Science ®Google Scholar
• Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A doubleblind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int. J Dermatol. 2004;43: 604–607.
   Google Scholar
• Hwang SW, Oh DJ, Lee D, Kim JW, Park SW. Clinical efficacy of 25% L-ascorbic acid (C’ensil) in the treatment of melasma. J Cutan Med Surg. 2009;13:74–81.
   PubMed Web of Science ®Google Scholar
• Itoh H. Functions and whitening effect of placenta. Fragrance J. 1990;6: 67–71.
   Google Scholar
• Hatae S, Mishima Y. Suppression of melanin production by bovine placental extract. Fragrance J. 1990;6:105–108.
   Google Scholar
• Masuda M, Tejima T, Suzuki T, . Skin lighteners. Cosmet Toil. 1996;111:65–77.
   Google Scholar
• Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for treatment of melasma. Dermatol Surg. 1996;22:443–447.
   PubMed Web of Science ®Google Scholar
• Ellis DA, Tan AK, Ellis CS. Superficial Micropeels: Glycolic Acid and Alpha-Hydroxy Acid with Kojic Acid. Facial Plast Surg. 1995;11:15–21.
   PubMedGoogle Scholar
• Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25:282–284.
   PubMed Web of Science ®Google Scholar
• Shimogaki H, Tanaka Y, Tamai H, Masuda M. In vitro and in vivo evaluation of ellagic acid on melanogenesis inhibition. Int. J. Cosmet. Sci. 2000;22:291–303.
   PubMedGoogle Scholar
• Kamide R, Arase S, Takiwaki H, . Clinical effects of XSC-29 formulation on UV-induced pigmentation. Nishinihon J Dermatol. 1995;57:136–142.
   Google Scholar
• Ertam I, Mutlu B, Unal I, Alper S, Alper S, . Efficiency of ellagic acid and arbutin in melasma: a randomized, prospective, open-label study. J Dermatol. 2008;35:570–574.
   PubMed Web of Science ®Google Scholar
• Imokawa G, Yada Y, Miyagishi M. Endothelins secreted from human keratinocytes are intrinsic mitogens for human melanocytes. J Biol Chem. 1992;267:24675–24680.
   PubMed Web of Science ®Google Scholar
• Imokawa G, Kobayashi T, Miyagishi M, Higashi K, Yada Y. The role of endothelin-1 in epidermal hyperpigmentation and signaling mechanisms of mitogenesis and melanogenesis. Pigment Cell Res. 1997;10:218–228.
   PubMedGoogle Scholar
• Ichihashi M, Kobayashi A, Okuda M, . Effect of chamomilla extracts application on UV-induced pigmentation. Skin Res (Hifu). 1999;41:475–480.
   Google Scholar
• Kawashima M, Okuda M, Kobayashi A, . Inhibitory effect of chamomilla extracts on UV-induced pigmentation. Nishinihon J Dermatol. 1999;61:682–685.
   Google Scholar
• Kim DS, Kim SY, Park SH, Choi YG, Kwon SB, . Inhibitory effects of 4-n-butylresorcinol on tyrosinase activity and melanin synthesis. Biol Pharm Bull. 2005;28: 2216–2219.
   PubMed Web of Science ®Google Scholar
• Katagiri T, Okubo T, Oyobikawa M, . Inhibitory action of 4-n-butylresorcinol (Rucinol®) on melanogenesis and its skin whitening effects. J Cosmet Chem Jpn. 2001;35: 42–49.
   Google Scholar
• Mafune E, Morimoto Y, Iizuka Y. Tranexamic acid and melasma. Farumashia. 2008;44:437–442.
   Google Scholar
• Chung WC, Shi GY, Chow YH, Chang LC, Hau JS, . Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells. Am. J. Physiol. 1993;264:C271–C281.
   Google Scholar
• Wang N, Zhang L, Miles L, Hoover-Plow J. Plasminogen regulates pro-opiomelanocortin processing. J Thromb Haemost. 2004;2:785–796.
   PubMed Web of Science ®Google Scholar
• Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, . Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: A preliminary clinical trial. Dermatol Surg. 2006;32:626–631.
   PubMed Web of Science ®Google Scholar
• Ando H, Matsui MS, Ichihashi M. Quasi-drugs developed in Japan for the prevention or treatment of hyperpigmentary disorders. Int J Mol Sci. 2010;11:2566–2575.
   PubMedGoogle Scholar
• Kawashima M, Mizuno A, Murata Y. Improvement of hyperpigmentation based on accelerated epidermal turnover: Clinical effects of disodium adenosine monophosphate in patients with melasma. Jpn J Clin Dermatol. 2008;62:250–257.
   Google Scholar
• Nakamura K, Yoshida M, Uchiwa H, . Down-regulation of melanin synthesis by a biphenyl derivative and its mechanism. Pigment Cell Res. 2003;16:494–500.
   PubMedGoogle Scholar
• Takeda K, Yokota T, Ikemoto T, . Inhibitory effect of a formulation containing 0.5percent Magnolignan® (5, 5′-dipropyl-biphenyl-2, 29-diol) on UV-induced skin pigmentation. Nishinihon J Dermatol. 2006;68:288–292.
   Google Scholar
• Takeda K, Arase S, Sagawa Y, . Clinical evaluation of the topical application of Magnolignan® (5, 59′-dipropyl-biphenyl-2, 2′-diol) for hyperpigmentation on the face. Nishinihon J Dermatol. 2006;68:293–298.
   Google Scholar
• Bleehen SS. The treatment of hypermelanosis with 4- isopropylcatechol. Br J Dermatol. 1976;94:687–694.
   PubMedGoogle Scholar
• Jimbow K. N-Acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the treatment of patients with melasma. Arch Dermatol 1991;172:1528–1534.
   Google Scholar
• Jimbow M, Marusyk H, Jimbow K. The in-vivo melanocytotoxicity and depigmenting potency of N-2, 4- acetoxyphenyl thioethyl acetamide in the skin and hair. Br J Dermatol. 1995;133:532–536.
   Google Scholar
• Costa A, Moisés TA, Cordero T, Alves CR, Marmirori J. Association of emblica, licorice and belides as an alternative to hydroquinone in the clinical treatment of melasma. An Bras Dermatol. 2010;85:613–620.
   PubMed Web of Science ®Google Scholar
• Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, . The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147:20–31.
   PubMed Web of Science ®Google Scholar
• Scherdin U, Bürger A, Bielfeldt S. Skin-lightening effects of a new face care product in patients with melasma. J Cosmet Dermatol. 2008;7:68–75.
   PubMedGoogle Scholar
• Lee MH, Kim HJ, Ha DJ. Therapeutic effect of topical application of lenoliec acid and lincomycin in combination with betamethasone valerate in melasma patients. J Korean Med Sci. 2002;17:518–523.
   PubMed Web of Science ®Google Scholar
• Anonymous. The Wealth of India – Raw Materials Vols. I–XI (1948–76) and Vols 1–3 Revised Series (1985–92). New Delhi: Council of Scientific and Industrial Research.
   Google Scholar
• Satyavati GV, Gupta AK, Tanabu N. Medicinal Plants of India Vol. 2 Council of Scientific and Industrial Research Publication. New Delhi: Indian Council of Medical Research, Cambridge printing worker; 1987. pp. XI+557.
   Google Scholar
• Draelos ZD. Topical agents used in association with cosmetic surgery. Sem Cut Med Surg. 1999;18:112–118.
   PubMedGoogle Scholar
• Keller KL, Fenske NA. Use of vitamins A, C, and E and related compounds in dermatology: A review. J Am Acad Dermatol. 1998;39:611–625.
   PubMed Web of Science ®Google Scholar
• Handog EB, Galang DA, de Leon-Godinez MA, Chan GP. A randomized, double-blind, placebo-controlled trial of oral procyanidin with vitamins A, C, E for melasma among Filipino women. Int J Dermatol. 2009;48:896–901.
   PubMed Web of Science ®Google Scholar
• Grekin RC, Shelton RM, Geisse JK, Frieden I, . 510-nm pigmented lesion dye laser: Its characteristics and clinical uses. J Dermatol Surg Oncol. 1993;19:380–387.
   PubMedGoogle Scholar
• Fitzpatrick RE, Goldman MP, Ruiz-Esparza J. Laser treatment of benign pigmented epidermal lesions using a 300 nanosecond pulse ad 510 nm wavelength. J Dermatol Surg Oncol. 1993;19:341–347.
   PubMedGoogle Scholar
• Dinehart SM, Waner M, Flock S. The copper vapor laser for treatment of cutaneous vascular and pigmented lesions. J Dermatol Surg Oncol. 1993;19:370–375.
   PubMedGoogle Scholar
• Goldberg DJ. Benign pigmented lesions of the skin: Treatment with Q- switched ruby laser. J Dermatol Surg Oncol. 1993;19:376–379.
   PubMedGoogle Scholar
• Manaloto RM, Alster T. Erbium YAG resurfacing for refractory melasma. Dermatol Surg. 1999;25:121–123.
   PubMed Web of Science ®Google Scholar
• Negishi K, Kushikata N, Takeuchi K. Photorejuvenation by intense pulsed light with objective measurement of skin color in Japanese patients. Dermatol Surg. 2006;32: 1380–1387.
   PubMed Web of Science ®Google Scholar
• Jeong SY, Chang SE, Bak H. New melasma treatment by collimated low fluence Q-switched Nd:YAG laser. Korean J Dermatol. 2008;46:1163–1170.
   Google Scholar
• Chan NP, Ho SG, Shek SY. A case series of facial depigmentation associated with low fluence Q-switched 1,064nm Nd:YAG laser for skin rejuvenation and melasma. Lasers Surg Med. 2010;42:712–719.
   PubMed Web of Science ®Google Scholar
• Polnikorn N. Treatment of refractory dermal melasma with the MedLite C6 Q-switched Nd:YAG laser: two case reports. J Cosmet Laser Ther. 2008;10:167–173.
   PubMed Web of Science ®Google Scholar
• Cho SB, Kim JS, Kim MJ. Melasma treatment in Korean women using a 1064-nm Q-switched Nd:YAG laser with low pulse energy. Clin Exp Dermatol. 2009;34:e847–850.
   PubMed Web of Science ®Google Scholar
• Lee HS, Won CH, Lee DH, . Treatment of melasma in Asian skin using a fractional 1,550-nm laser: An open clinical study. Dermatol Surg. 2009;35:1499–1504.
   PubMed Web of Science ®Google Scholar
• Kroon MW, Wind BS, Beek JF, . Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: A randomized controlled pilot study. J Am Acad Dermatol. 2011;64:516–523.
   PubMed Web of Science ®Google Scholar
• Lee HI, Lim YY, Kim BJ, . Clinicopathologic efficacy of copper bromide plus/yellow laser (578 nm with 511 nm) for treatment of melasma in Asian patients. Dermatol Surg. 2010;36:885–893.
   PubMed Web of Science ®Google Scholar
• Dawber RPR, Walker NPJ. Physical and Surgical therapy. In: Champion RH, Burns BA, editors. Text book of Dermatology. 6th ed. London: Blackwell Scientific Publications; 1998. pp. 3573–3575.
   Google Scholar
• Cotellessa C, Peris K, Fargnoli MC, . Microdermabrasion vs Microdermabrasion followed by 15% TCA for treatment of cutaneous hyperpigmentation in adult females. Dermatol Surg. 2003;29:352–356.
   PubMedGoogle Scholar
• Moy LS, Murad H, Moy RL. Superficial chemical peels, in Cutaneous Surgery. In: Wheeland RG, ed. 1st ed. Philadelphia: WB Saunders company. 1994. pp. 463–478.
   Google Scholar
• Kodali S, Guevara IL, Carrigan CR, . A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol. 2010;63:1030–1035.
   PubMed Web of Science ®Google Scholar
• Monheit GD. The Jessner's- trichloroacetic acid peel. An enhanced medium-depth chemical peel. Dermatol Clin. 1995;13:277–283.
   PubMed Web of Science ®Google Scholar
• Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of Melasma in dark skinned patients. Dermatol Surgery. 2002;28:828–832.
   PubMed Web of Science ®Google Scholar
• Hurley ME, Guevara IL. Gonzales RM, . Efficacy of glycolic acid peels in treatment of melasma. Arch Dermatol 2002;138:1578–1582.
   PubMedGoogle Scholar
• Sehgal VN, Luthra A, Aggarwal AK. Evaluation of graded strength glycolic acid (GA) facial peel: an Indian experience. J Dermatol. 2003;30:758–761.
   PubMedGoogle Scholar
• Gupta AK, Gover MD, Nouri K, . The treatment of melasma: a review of clinical trials. J Am Acad Dermatol. 2006;55:1048–1065.
   PubMed Web of Science ®Google Scholar
• Grimes PE. The safety and efficacy of salicylic acid chemical peels in darker racial-ethnic groups. Dermatol Surg. 1999;25:18–22.
   PubMed Web of Science ®Google Scholar
• Kodali S, Guevara IL, Carrigan CR, Daulat S, Blanco G, . A prospective, randomized, split-face, controlled trial of salicylic acid peels in the treatment of melasma in Latin American women. J Am Acad Dermatol. 2010;63: 1030-1035.
   PubMed Web of Science ®Google Scholar
• Ejaz A, Raza N, Iftikhar N, Muzzafar F. Comparison of 30% salicylic acid with Jessner’s solution for superficial chemical peeling in epidermal melasma. J Coll Physicians Surg Pak. 2008;18:205–208.
   PubMed Web of Science ®Google Scholar
• 150 Sarkar R, Kaur C, Bhalla M, Kanwar AJ. The combination of glycolic acid peels with a topical regimen in the treatment of melasma in dark-skinned patients: a comparative study. Dermatol Surg. 2002;28:828–832.
   PubMedGoogle Scholar
• 151 Erbil H, Sezer E, Tastan B, Arca E, Kurumlu Z. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol. 2007;34:25–30.
   PubMedGoogle Scholar
• Lim JT, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg. 1997;23: 177–179.
   PubMed Web of Science ®Google Scholar
• Rendon M, Cardona LM, Bussear EW, Benitez AL, Colón LE, Johnson LA, . Successful treatment of moderate to severe melasma with triple-combination cream and glycolic acid peels: a pilot study. Cutis. 2008;82: 372–378.
   PubMedGoogle Scholar
• Hurley ME, Guevara IL, Gonzales RM, Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol. 2002;138:1578–1582.
   PubMedGoogle Scholar
• Kalla G, Garg A, Kachhawa D. Chemical peeling—glycolic acid versus trichloroacetic acid in melasma. Indian J Dermatol Venereol Leprol. 2001;67:82–84.
   PubMedGoogle Scholar
• Soliman MM, Ramadan SA, Bassiouny DA, . Combined trichloroacetic acid peel and topical ascorbic acid versus trichloroacetic acid peel alone in the treatment of melasma: a comparative study. J Cosmet Dermatol. 2007;6:89–94.
   PubMedGoogle Scholar
• Sharquie KE, Al-Tikreety MM, Al-Mashhadani SA. Lactic acid chemical peels as a new therapeutic modality in melasma in comparison to Jessner’s solution chemical peels. Dermatol Surg. 2006;32:1429–1436.
   PubMed Web of Science ®Google Scholar
• Lawrence N, Cox SE, Brody HJ. Treatment of melasma with Jessner’s solution versus glycolic acid: A comparison of clinical efficacy and evaluation of the predictive ability of Wood’s light examination. J Am Acad Dermatol. 1997;36:589–593.
   PubMed Web of Science ®Google Scholar
• Khunger N, Sarkar R, Jain RK. Tretinoin peels versus glycolic acid peels in the treatment of melasma in dark-skinned patients. Dermatol Surg. 2004;30:756–760.
   PubMed Web of Science ®Google Scholar
• Ilknur T, Biçak MU, Demirtağlu M, . Glycolic acid peels versus amino fruit acid peels in the treatment of melasma. Dermatol Surg. 2010;36:490–495.
   PubMedGoogle Scholar
• Berardesca E, Cameli N, Primavera G, . Clinical and instrumental evaluation of skin improvement after treatment with a new 50% pyruvic acid peel. Dermatol Surg. 2006;32: 526–531.
   PubMed Web of Science ®Google Scholar